Catalio Capital Management’s Cytokinetics CYTK Stock Holding History

Catalio Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-215,501	Closed	-$14.2M	–	43
2026 Q1	$14.2M	Sell	215,501 -42,880	-17%	-$2.73M	2.97%	13
2025 Q4	$16.4M	Sell	258,381 -193,200	-43%	-$12M	2.9%	13
2025 Q3	$24.8M	Sell	451,581 -149,858	-25%	-$6.17M	4.59%	10
2025 Q2	$19.9M	Buy	601,439 +15,627	+3%	+$544K	4.17%	9
2025 Q1	$23.5M	Buy	585,812 +128,225	+28%	+$5.89M	5.73%	6
2024 Q4	$21.5M	Buy	+457,587	New	+$23.8M	4.71%	10

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalio Capital Management's CYTK Position: Q2 2026 in Review

Catalio Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 215,501 shares — an estimated $14.2M sold.

Catalio Capital Management first reported a position in CYTK in Q4 2024 and held it in 6 quarters. The position peaked at $24.8M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Catalio Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Catalio Capital Management sold 215,501 Cytokinetics shares in Q2 2026, an estimated $14.2M.
Catalio Capital Management first reported a position in Cytokinetics in Q4 2024 and held it in 6 quarters.
Catalio Capital Management's Cytokinetics position peaked at $24.8M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.